Seeking Alpha

The FDA has granted a priority review to Celgene's (CELG +2.1%) Revlimid drug for patients with...

The FDA has granted a priority review to Celgene's (CELG +2.1%) Revlimid drug for patients with relapsed or refractory mantle cell lymphoma (MCL) after prior therapy. Revlimid, in combination with the steroid dexamethasone, has also won approval from China's State Food & Drug Administration for use in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs